Embecta to Acquire Owen Mumford for Up to £150 Million
Event summary
- Embecta Corp. has agreed to acquire Owen Mumford Holdings Limited for up to £150 million, including £100 million upfront and £50 million in performance-based payments.
- The deal is expected to close in Embecta’s fiscal third quarter of 2026, subject to regulatory approvals.
- Owen Mumford generated £69.4 million in revenue during fiscal year 2025, with 80% coming from the UK and U.S.
- Embecta plans to finance the acquisition with borrowings under its revolving credit facility.
The big picture
Embecta’s acquisition of Owen Mumford marks a strategic shift towards becoming a broad-based medical supplies company, expanding its portfolio to include drug delivery platforms for pharmaceutical partners. This move aligns with industry trends towards consolidation in the medical device sector, particularly in chronic care markets like diabetes, obesity, and autoimmune diseases. The deal underscores Embecta’s commitment to leveraging its global commercial infrastructure to drive innovation and scale.
What we're watching
- Integration Challenges
- How Embecta will merge Owen Mumford’s device design and manufacturing capabilities with its own global commercial infrastructure.
- Revenue Growth
- Whether the acquisition will sustainably improve Embecta’s revenue growth trajectory in fiscal year 2027 and beyond.
- Geographic Expansion
- The pace at which Embecta can leverage Owen Mumford’s products to broaden its geographic reach beyond the UK and U.S.
Related topics